For patients with metastatic or recurrent RCC, molecularly targeted therapies such as multi-targeted receptor tyrosine kinase (RTK) or mTOR inhibitors are frequently employed as RCC therapy nowadays. The gene discussed is MTOR; the disease is renal cell carcinoma.